Three-year follow-up of malignancies in tacrolimus-treated renal recipients - An analysis of European multicentre studies

Clinical Transplantation

Volumn 22, Issue 3, 2008, Pages 372-377

  Cowlrick, Ivor ^a   Delventhal, H ^a   Kaipainen, K ^a   Krcmar, C ^a   Petan, J ^a   Schleibner, S ^a  

^a Astellas Pharma GmbH   (Germany)

Author keywords

Malignancy; Renal transplantation; Review; Tacrolimus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL CANCER; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED CANCER; DRUG SAFETY; EUROPE; EVIDENCE BASED MEDICINE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOMA; MELANOMA; NONHODGKIN LYMPHOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT CANCER; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; UROGENITAL TRACT CANCER;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOMA; MYCOPHENOLIC ACID; NEOPLASMS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TACROLIMUS; TIME FACTORS;

EID: 43749115145     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00796.x     Document Type: Review

References (27)

1. Mayer AD, Dmitrewski J, Squifflet J-P et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997: 64: 436.
2. Margreiter R for the European Tacrolimus vs. Ciclosporin Microemulsion Renal T ransplant Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised mutlicentre study. Lancet 2002: 359: 741.
3. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005: 79: 807.
4. Vincenti F. A decade of progress in kidney transplantation. Transplantation 2004: 77: S52.
5. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005: 331: 810.
6. Morales JM, Domínguez-Gil B. Impact of tacrolimus and mycophenolate mofetil on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol 2006: 17: S296.
7. Pilmore H. Choice of calcineurin inhibitors in adult renal transplantation. Effects on transplant outcomes. Nephrology 2007: 12: S88.
8. Morath C, Muelluer M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 2004: 15: 1582.
9. Kaplan B, Schold J, Meier-Kriesche H-U. Overview of large database analysis in renal transplantation. Am J Transplant 2003: 3: 1052.
10. Henze N. Stochastik für Einsteiger. Wiesbaden, Germany: Vieweg Verlag, 2004, 5. Auflage, ISBN 3-528-46894-7.
11. Mayer AD for the E uropean Multicentre Renal Study Group. Four-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 1999: 31: 27S.
12. Mayer AD for the European Multicentre Renal Study Group. Chronic rejection and graft half-life. Five-year follow-up of the European Tacrolimus Multicentre Renal Study. Transplant Proc 2002: 34: 1491.
13. Montagnino G, Krämer BK, Arias M for the European Tacrolimus vs. Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: Twelve-month follow-up. Transplant Proc 2002: 34: 1635.
14. Krämer BK, Montagnino G, del Castillo D et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2year follow-up results. Nephrol Dial Transplant 2005: 20: 968.
15. Krämer BK, Montagnino G, Arias M, Pascual J for the Tacrolimus vs. Cyclosporin Follow - up Study Group. Tacrolimus vs. cyclosporin microemulsion: 3-year follow-up of a large multicentre trial. Am J Transplant 2003: 3 (Suppl. 5): 464.
16. Vanrenterghem Y, van Hooff JP, Squifflet J-P et al. Minimization of immunosuppressive therapy after renal transplantation: Results of a randomized controlled trial. Am J Transplant 2005: 5: 87.
17. Pascual J, van Hooff JP, Salmela K et al. Randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006: 82: 55.
18. Segoloni G, Bonomini V, Maresca MC et al. Tacrolimus is highly effective in both dual and triple therapy regimens following renal transplantation. Tranpl Int 2000: 13 (Suppl.1): S336.
19. Calconi G, Vianello A for the Italian and Spanish Tacrolimus Study Group. One-year follow-up of a large European trial comparing dual versus triple tacrolimus-based immunosuppressive regimens following renal transplantation. Transplant Proc 2001: 33: 1021.
20. Garcia I for the Spanish Italian Tacrolimus Study Group. Efficacy and safety of duel versus triple tacrolimus-based therapy in kidney transplantation: Two-year follow-up. Transplant Proc 2002: 34: 1638.
21. Pascual J, Segoloni M, Gonzalez Molina M et al. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: Results of a European trial with 3-year follow-up. Transplant Proc 2003: 35: 1701.
22. Mourad G, Cantarell C, Rigotti P, Budde K. Multicentre, follow-up study to assess the long-term efficacy and safety of a tacrolimus/ mycophenolate mofetil regimen with daclizumab vs. standard treatment with steroids in kidney transplantation. Transplant Int 2007: 20 (Suppl. 2): 26. Abstract O091 Presented at the 13th Congress of the European Society for Organ Transplantation, Prague, Czech Republic.
23. K auffman HM, C herikh WS, M c B ride MA, C heng Y, H anto DW. Post-transplant de novo malignancies in renal transplant recipients: The past and present. Transplant Int 2006: 19: 607.
24. Pedotti P, Cardillo M, Rossini G et al. Incidence of cancer after kidney transplant: Results from the North Italy Transplant Program. Transplantation 2003: 76: 1448.
25. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15 183 recipients. Am J Transplant 2007: 7: 2140.
26. Cancer Research UK: Demographics of the European Union. Available at: http://info.cancerresearchuk.org/cancerstats/ (accessed October 2007).
27. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005: 16: 481.